ckdpharm.comCrawled Nov 8, 2026
The page introduces Jongkeun-dang’s pharmaceutical products, including Penjal, Prepemin, and Itonque, alongside research and development updates.
The page introduces Jongkeun-dang’s pharmaceutical products, including Penjal, Prepemin, and Itonque, alongside research and development updates.
Chong Kun Dang establishes **Neurateon** to advance technological innovation in healthcare and **Achela** to develop new pharmaceutical drugs. The move expands the company’s research capabilities across AI-driven diagnostics and next-generation therapeutics. Both subsidiaries will operate under Chong Kun Dang’s broader strategy to strengthen its biotech and pharmaceutical pipeline.
Oct 2026The Chosun DailyNews article
Chong Kun Dang is constructing a **2.2 trillion won ($1.64 billion) biopharmaceutical industrial complex** in Siheung, Gyeonggi Province. The facility will be developed in the Baegot planned community, marking a major expansion of the company’s manufacturing and research capabilities. The project reflects Chong Kun Dang’s push into large-scale pharmaceutical production infrastructure.
Sep 2026The Korea HeraldNews article
Chong Kun Dang secures regulatory approval to advance CKD-339, a combination drug candidate for hypertension, into a domestic Phase 3 clinical trial. The Ministry of Food and Drug Safety grants the green light for the next-stage testing, marking a critical step in the drug’s development pipeline. CKD-339 combines multiple active ingredients to address high blood pressure, a condition affecting millions globally.
Jul 2026The Herald BusinessNews article
Chong Kun Dang is expanding its domestic and international R&D partnerships to accelerate the development of innovative pharmaceuticals. The company is establishing dedicated research hubs in Korea to support global drug discovery efforts. These moves aim to strengthen its pipeline of novel treatments through collaborative and localized development strategies.
Jul 2026CHOSUNBIZNews article
